Literature DB >> 25510636

Micro-invasive suture trabeculotomy after canaloplasty: preliminary results.

Bogomil Voykov1, Peter Szurman1,2, Spyridon Dimopoulos1, Focke Ziemssen1, Omar Alnahrawy1.   

Abstract

BACKGROUND: In this study, a conjunctival-sparing ab interno approach for circumferential trabeculotomy, termed micro-invasive suture trabeculotomy (MIST) and its preliminary results are presented.
DESIGN: Retrospective case-series in a university setting. PARTICIPANTS: A total of 31 patients with open-angle glaucoma with history of canaloplasty.
METHODS: A conjunctival-sparing ab interno approach for circumferential trabeculotomy, termed MIST. MAIN OUTCOME MEASURES: Mean decrease of intraocular pressure (IOP) and number of pressure-lowering medications.
RESULTS: Mean decrease of IOP was 11.1 mmHg (standard deviation [SD], 9.9 mmHg) at 6 months, 12.1 mmHg (SD, 10.5 mmHg) at 12 months and 13.5 mmHg (SD, 11.4 mmHg) at 24 months. The average percent lowering of IOP was 36.7% (SD, 32.8%) at 6 months, 41.4% (SD, 35.9%) at 12 months and 44.6% (SD, 37.7%) at 24 months. The number of pressure-lowering medications decreased by 1.1 (SD, 1.3) at month 6, by 1.2 (SD, 1.5) at month 12, and by 1.3 (SD, 1.6) at month 24.
CONCLUSIONS: MIST is a promising approach for the treatment of open-angle glaucoma, which is insufficiently controlled with canaloplasty. The procedure achieved significant and sustained lowering of the intraocular pressure and demonstrated an excellent safety profile. The main advantages of the procedure are: easy to learn, fast to perform, and sparing of the conjunctiva for further filtration surgery, if necessary.
© 2014 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Keywords:  glaucoma; glaucoma incisional surgery; new treatments

Mesh:

Substances:

Year:  2015        PMID: 25510636     DOI: 10.1111/ceo.12482

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  8 in total

1.  Micro-invasive 360-degree suture trabeculotomy after successful canaloplasty – one year results.

Authors:  Anna-Maria Seuthe; Kai Januschowski; Peter Szurman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-01       Impact factor: 3.117

2.  Modified canaloplasty with suprachoroidal drainage versus conventional canaloplasty-1-year results.

Authors:  Anna-Maria Seuthe; Ciprian Ivanescu; Stephan Leers; Karl Boden; Kai Januschowski; Peter Szurman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-05-10       Impact factor: 3.117

Review 3.  [Revision procedures after canaloplasty].

Authors:  B Voykov; J M Rohrbach
Journal:  Ophthalmologe       Date:  2016-11       Impact factor: 1.059

4.  Systematic review and Meta-analysis of treating open angle glaucoma with gonioscopy-assisted transluminal trabeculotomy.

Authors:  Chun-Yan Guo; Xiao-Hui Qi; Jian-Ming Qi
Journal:  Int J Ophthalmol       Date:  2020-02-18       Impact factor: 1.779

5.  Combined Gonioscopy-Assisted Transluminal Trabeculotomy (GATT) with Ab Interno Canaloplasty (ABiC) in Conjunction with Phacoemulsification: 12-Month Outcomes.

Authors:  Ahmed Al Habash; Muath Alrushoud; Omar Al Abdulsalam; Abdulaziz Ismail Al Somali; Mohanna Aljindan; Adel Salah Al Ahmadi
Journal:  Clin Ophthalmol       Date:  2020-08-25

Review 6.  Canaloplasty in the Treatment of Open-Angle Glaucoma: A Review of Patient Selection and Outcomes.

Authors:  Ivano Riva; Paolo Brusini; Francesco Oddone; Manuele Michelessi; Robert N Weinreb; Luciano Quaranta
Journal:  Adv Ther       Date:  2018-11-28       Impact factor: 3.845

Review 7.  Circumferential canal surgery: a brief history.

Authors:  Jaime E Dickerson; Reay H Brown
Journal:  Curr Opin Ophthalmol       Date:  2020-03       Impact factor: 4.299

8.  Intermediate outcomes of ab externo circumferential trabeculotomy and canaloplasty in POAG patients with prior incisional glaucoma surgery.

Authors:  Huaizhou Wang; Chen Xin; Ying Han; Yan Shi; Sarah Ziaei; Ningli Wang
Journal:  BMC Ophthalmol       Date:  2020-10-02       Impact factor: 2.209

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.